Sugi Predict

Sugi Predict / Compounds / SCHEMBL3321269

SCHEMBL3321269

SCHEMBL3321269

Cc1ccc(C(=O)NC2CC2)cc1Nc1nc(-c2ccc(NC(=O)CNC(=O)OC(C)(C)C)cc2)c(C(=O)NCc2ccccc2)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 7/20 0.41
▸ MAPK11 Q15759 4/20 0.40
▸ TTK P33981 2/20 0.38
▸ MAPT P10636 3/20 0.38
▸ TP53 P04637 1/20 0.38
▸ NAMPT P43490 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ HDAC1 Q13547 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ PPARG P37231 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NCOA2 Q15596 1/20 0.37
▸ NCOA1 Q15788 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ GBA1 P04062 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ DHODH Q02127 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3318071 0.94 GBA1 (0.41) MAPK14MAPK11TTKMAPTTP53
SCHEMBL3311987 0.94 MAPK14 (0.42) MAPK14MAPK11MAPTTP53NAMPT
SCHEMBL13534505 0.88 MAPK14 (0.43) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL3320357 0.88 MAPK14 (0.42) MAPK14MAPK11TTKMAPTTP53
SCHEMBL3835446 0.88 MAPK14 (0.43) MAPK14MAPK11MAPTTP53LMNA
Trifluoroacetic Acid SCHEMBL3316074 0.86 MAPK14 (0.40) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL13538849 0.86 MAPK14 (0.36) MAPK14MAPK11HDAC1HDAC6
SCHEMBL27635999 0.86 MAPK14 (0.50) MAPK14MAPK11MAPTTP53LMNA
Trifluoroacetic Acid SCHEMBL3316710 0.85 MAPK14 (0.40) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL3346606 0.85 MAPT (0.49) MAPK14MAPK11MAPTTP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 — — US claimed
EP-1635824-B1 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2009-08-19 — — EP claimed
EP-1635824-A2 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS Novartis AG (CH) 2006-03-22 — — EP claimed
WO-2005000298-A2 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2005-01-06 — — WO claimed
US-20040254236-A1 P-38 inhibitors NOVARTIS AG (CH) 2004-12-16 — — US claimed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 — — US disclosed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 — — US disclosed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 — — US disclosed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 — — US disclosed
EP-1635824-B1 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2009-08-19 — — EP disclosed
EP-1635824-B1 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2009-08-19 — — EP disclosed
US-20040254236-A1 P-38 inhibitors NOVARTIS AG (CH) 2004-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004298-A1 P-38 INHIBITORS MAPK8, MAPK1, MAP3K8 MAPK14 21/4885MAPK11 38/4885TTK 509/4885
US-20040254236-A1 P-38 inhibitors MAPK8, MAP3K8, MAPK1 MAPK14 12/4885MAPK11 41/4885TTK 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.